Physician profile
Evan Selsky
NPI 1659365682
$857.88
in general payments reported to CMS, 2019-2025
11 companies · $439 in 2025
The $439 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2024: $294 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $732.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.01 | 2024-2025 | Jardiance |
| Genzyme Corporation | $125.00 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $122.26 | 2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $106.99 | 2024-2025 | |
| Pfizer INC. | $87.69 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $73.37 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $58.65 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $40.95 | 2024-2025 | Camzyos, Eliquis |
| Scpharmaceuticals INC. | $32.96 | 2025 | |
| Amgen INC. | $29.90 | 2024 | Repatha |
| Watermark Medical, INC. | $28.10 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Selsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.